Q-SYMBIO randomized 420 patients with moderate-to-severe heart failure to CoQ10 100 mg three times daily or placebo added to standard therapy. Short-term (16-week) NYHA class, six-minute walk and NT-proBNP endpoints did not significantly improve, but over 2 years the composite major-cardiovascular-event endpoint was lower with CoQ10 (15% vs 26%, hazard ratio 0.50, 95% CI 0.32-0.80, P=.003), as were cardiovascular mortality, all-cause mortality and heart-failure hospitalization. It did not test prevention of steroid-related cardiac injury, and the trial report does not specify the product/brand used.[1]
- Selected heart-failure population receiving standard therapy; findings do not apply automatically to healthy users, and the unspecified product/brand means results do not transfer to every ubiquinol/ubiquinone product.
- Abstract-checked; no qualified clinical review.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.
· Reopened the PubMed structured abstract via E-utilities, added exact event rates/HR/CI and secondary-endpoint P values, and confirmed the single linked PubMed notice (PMID 25282030) is editorial commentary (RefType=CommentIn), not a retraction. Independent editorial review pending; no qualified clinical review.